Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06GTS
|
|||
| Former ID |
DIB019199
|
|||
| Drug Name |
PMID24556381C10l
|
|||
| Synonyms |
GTPL8603; BDBM50449284
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C23H15N3O2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC(=NC3=C2C=C(C=C3)[N+](=O)[O-])C4=CNC5=CC=CC=C54
|
|||
| InChI |
1S/C23H15N3O2/c27-26(28)16-10-11-22-19(12-16)18(15-6-2-1-3-7-15)13-23(25-22)20-14-24-21-9-5-4-8-17(20)21/h1-14,24H
|
|||
| InChIKey |
LQGHUZLZFHCQPO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bile-salt-activated lipase (CEL) | Target Info | Inhibitor | [1] |
| Neutrophil elastase (NE) | Target Info | Inhibitor | [1] | |
| BioCyc | Triacylglycerol degradation | |||
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.